Navigation Links
Wyeth Announces Holder Right to Surrender Convertible Debentures
Date:6/16/2009

ery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products, nutritionals and non-prescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.

The statements in this press release that are not historical facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, among others, risks related to our proposed merger with Pfizer, including satisfaction of the conditions of the proposed merger on the proposed timeframe or at all, contractual restrictions on the conduct of our business included in the merger agreement, and the potential for loss of key personnel, disruption in key business activities or any impact on our relationships with third parties as a result of the announcement of the proposed merger; the inherent uncertainty of the timing and success of, and expense associated with, research, development, regulatory approval and commercialization of our products and pipeline products; government cost-containment initiatives; restrictions on third-party payments for our products; substantial competition in our industry, including from branded and generic products; emerging data on our products and pipeline products; the importance of strong performance from our principal products and our anticipated new product introductions; the highly regulated nature of our business; product liability, intellectual property and other litigation risks and environmental liabilities; the outcome of government investigations; uncertainty regarding our intellectual property rights and those of others; difficulties associated with, and regulatory compliance with respect to, manufacturing of our products; risks associated with our st
'/>"/>

SOURCE Wyeth
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Wyeth Declares Common Stock Dividend
2. New Phase 3 Data Continue to Indicate that Wyeths Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease
3. Wyeth Sets Webcast and Conference Call For 2009 Second Quarter Earnings
4. Wyeth Announces Full Redemption of $2 Convertible Preferred Stock
5. Wyeth Declares Common and Preferred Stock Dividends
6. Wyeth Sets Webcast and Conference Call for 2009 First Quarter Earnings
7. Wyeth to Present at the SG Cowen & Co. 29th Annual Healthcare Conference
8. Wyeth to Present at the Goldman Sachs Healthcare CEOs Unscripted Conference
9. Wyeth Names Michael Kamarck President, Technical Operations & Product Supply
10. Wyeth Declares Preferred Stock Dividend
11. Wyeth Reports Earnings Results for the 2008 Third Quarter and First Nine Months
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 2015 GliaCure, a privately-held biotechnology company ... neurological and neuropsychiatric disorders based on glial targets, ... patients in a Phase 1b clinical trial of ... as a potential disease-modifying treatment. GliaCure,s innovative approach ... it both promotes the clearance of amyloid and ...
(Date:5/4/2015)... /PRNewswire/ - Fluorinov Pharma (Fluorinov), a FACIT portfolio ... Dr. Roger J Garceau, to its Board of ... matters including corporate development and clinical strategy, his ... regulatory expertise as Fluorinov transitions to clinical development.  ... of pharmaceutical development experience to Fluorinov and most ...
(Date:5/4/2015)... May 04, 2015 Genedata, a ... discovery and life science research, today announced the ... latest version of its enterprise solution for biologics ... enables more efficient discovery and development of novel ... integrate and address protein optimization and developability requirements. ...
(Date:5/4/2015)... May 4, 2015 China Cord Blood Corporation ... China,s leading provider of cord blood ... cell storage services, today announced that the Company has ... a Hong Kong listed company ... into an agreement (the "Agreement") to purchase the Company,s ...
Breaking Biology Technology:GliaCure Initiates Phase 1b Dosing in Alzheimer's Patients 2Roger J Garceau joins Fluorinov board, adds clinical expertise to bromodomain program and oncology pipeline 2Roger J Garceau joins Fluorinov board, adds clinical expertise to bromodomain program and oncology pipeline 3Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 2Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 3Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 4China Cord Blood Corporation Receives Notice of a Transaction Regarding its 7% Senior Convertible Notes Due 2017 Held by KKR 2China Cord Blood Corporation Receives Notice of a Transaction Regarding its 7% Senior Convertible Notes Due 2017 Held by KKR 3
... the Middle Class Using India,s Private Health Care System, ... be an Increasing Need for Diagnostic Imaging Equipment, ... that growing demand for private health care in India ... a result, the,market will experience rapid growth, reaching a ...
... Ventures, Khosla Ventures, Kleiner Perkins ... and TPG Ventures, Strong Endorsement of Technology Pioneer at Forefront of Developing ... ... development of renewable hydrocarbon biofuels, today,announced that it closed the first tranche of ...
... ,Arpida Ltd (SWX: ARPN) was invited to present ... antimicrobial agents at the 47th annual,Interscience Conference on ... a major scientific conference where thousands of,scientists and ... discuss the,latest developments in the field of infectious ...
Cached Biology Technology:Not Just for the Rich: India's Private Health Care is Booming 2Amyris Biotechnologies Announces $70 Million Series B Round 2Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC 2Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC 3
(Date:4/27/2015)... Apr. 27, 2015 Profile Solutions, Inc. (OTC: ... security systems is pleased to announce that Dr ... consultant and member of its scientific advisory board. ... as a thought leader in technology-enhanced learning models. He ... and has published studies and books focused on online ...
(Date:4/14/2015)... , April 14, 2015  HYPR Corp. today ... (FIDO ® ) Alliance tm , an industry ... members commit to share technology and collaborate to ... are interoperable, more secure and private, and easier ... identity verification that protects sensitive user information and ...
(Date:4/9/2015)... Synaptics Inc. (NASDAQ: SYNA ), a leading ... will report financial results for the third quarter of ... close of market. The company will host a corresponding ... PT (5:00 p.m. ET), during which management may discuss ... live call, analysts and investors should dial 888-438-5524 (conference ...
Breaking Biology News(10 mins):Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Synaptics to Report Third Quarter Results on April 23 2
... If that office inkjet printer has become just another ... Similar technology may soon be used to develop paper-based ... food poisoning or be used as bioterrorism agents. In ... Chemistry , John Brennan and his research team at McMaster ...
... The destructive cellular pathways activated in Alzheimer,s disease ... researchers from Georgetown University Medical Center (GUMC). They ... successfully target both conditions. In an oral ... on Alzheimer,s Disease, the scientists will show that ...
... June 22 The Federal Bureau of Investigation (FBI) ... a five-year, $47 million contract to continue managing the ... Service (CSS) program. The contract covers the conversion of ... electronic records for the FBI. , , ...
Cached Biology News:Toxin detection as close as an inkjet printer 2Alzheimer's disease drug treats traumatic brain injury, report GUMC researchers 2Federal Bureau of Investigation Awards Lockheed Martin Biometric Card Scanning Service Contract 2
Rabbit Anti-Ferret Whole Serum Antibody, Unconjugated...
... Molecular Imaging's proprietary Focus™ detector technology, while ... the R4. The microPET Focus 120 ... avaiable PET scanner. Focus scanners also ... scinitallor based PETsystems. The combination of ...
... pAcGHLT-A,B,C ... Vector Set,pAcGHLT-XylE ... Vector,Thrombin Powder,Thrombin ... Inhibitor Cocktail,Insect ...
... has been developed to significantly increase the ... Stability is increased at room temperature ... This product is subjected to 0.45 ... azide. This formulation insures consistently high ...
Biology Products: